

Author Index

Volume 251 (1996)

- Adamson, U., see Carlsson, T. **251**, 187
Aoki, Yoko., see Suzuki, Y. **251**, 41
- Beck, M., E. Scheuring, H.-U. Voelter, J. Brandt, K. Harzer, Neuraminidase assay in cultured human fibroblasts: in situ versus in vitro procedures
Benson, D., see Yamada, T. **251**, 207
Beuers, U., see Fischer, S. **251**, 173
Beyersdorf, F., see Oremek, G.M. **251**, 201
Bhavanandan, V.P., A. Martin, D.R. Erickson, Quantitation of urinary glycosaminoglycans with Alcian blue: evaluation of the interference by Tamm-Horsfall glycoprotein
Brandt, J., see Beck, M. **251**, 163
- Calam, D.H., see Lessinger, J.-M. **251**, 119
Calam, D.H., see Canalias, F. **251**, 145
Gubern, G., F. Canalias, F. Javier Gella, E. Colinet, C. Profilis, D.H. Calam, F. Ceriotti, J. Dufaux^c, A.G. Hadjivassiliou, J.M. Lessinger, K. Lorentz, A. Vassault, Production and certification of an enzyme reference material for pancreatic α -amylase (CRM 476) **251**, 145
Carlsson, T., U. Adamson, P.-E. Lins, B. Danielsson, Use of an enzyme thermistor for semi-continuous blood glucose measurements **251**, 187
Ceriotti, F., see Canalias, F. **251**, 145
Colinet, E., see Canalias, F. **251**, 145
- Danielsson, B., see Carlsson, T. **251**, 187
Das, R.G., see Lessinger, J.-M. **251**, 119
Dourson, J.-L., see Lessinger, J.-M. **251**, 119
Dufaux, J., see Gubern, G. **251**, 145
- Erickson, D.R., see Bhavanandan, V.P. **251**, 207
- Férard, G., see Lessinger, J.-M. **251**, 119
- Gella, F.J., see Gubern, G. **251**, 145
Gubern, G., F. Canalias, F.J. Gella, E. Colinet, C. Profilis, D.H. Calam, F. Ceriotti, J. Dufaux^c, A.G. Hadjivassiliou, J.M. Lessinger, K. Lorentz, A. Vassault, Production and certification of an enzyme reference material for pancreatic α -amylase (CRM 476) **251**, 145
- Hadjivassiliou, A.G., see Gubern, G. **251**, 145
Harzer, K., see Beck, M. **251**, 163
Hempel, A., see Vorderwinkler, K.-P. **251**, 113
Hosoda, Y.O., see Kaneko, N. **251**, 65
Howanitz, P.J., see Steindel, S.J. **251**, 25
- Ichimura, T., see Ohta, M. **251**, 81
Itoh, N., see Ohta, M. **251**, 81
Itoh, Y., see Yamada, T. **251**, 105
- Kajita, T., see Kaneko, N. **251**, 65
Kaneko, N., R. Matsuda, S. Hosoda, T. Kajita, Y. Ohta, Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction **251**, 65
Kawai, T., see Yamada, T. **251**, 105
Kazuta, Y., see Suzuki, Y. **251**, 41
Koebe, H.-G., see Fischer, S. **251**, 173
Kostner, G.M., see Oettl, K. **251**, 131
- Lessinger, J.-M., G. Férard, V. Mignot, D.H. Calam, R.G. Das, J.-L. Dourson, Catalytic properties and stability of lipase purified from human pancreatic juice **251**, 119

- Lessinger, J.M., see Gubern, G. **251**, 145
Li, Xue, see Suzuki, Y. **251**, 41
Lins, P.-E., see Carlsson, T. **251**, 187

Mair, J., see Vorderwinkler, K.-P. **251**, 113
Malle, E., see Oettl, K. **251**, 131
Martin, A., see Bhavanandan, V.P. **251**, 207
Matsuda, R., see Kaneko, N. **251**, 65
Mignot, V., see Lessinger, J.M. **251**, 119
Miida, T., see Yamada, T. **251**, 105
Miyabayashi, S., see Suzuki, Y. **251**, 41

Narisawa, K., see Suzuki, Y. **251**, 41
Nishimura, M., see Ohta, M. **251**, 81

Ohta, K., see Ohta, M. **251**, 81
Ohta, M., H. Obayashi, T. Ichimura, M. Nishimura, N. Itoh, K. Ohta, Immunological characterization of antibodies against synthetic peptides of glutamic acid decarboxylase **251**, 81
Oremek, G.M., U.B. Seiffert, F. Beyersdorf, Kinetic differences between creatine kinase-isoenzyme MB (CK-MB) and c-troponin-T in patients with myocardial damage **251**, 201

Piper, H.M., see Vorderwinkler, K.-P. **251**, 113
Pitkänen, E., Mannose, mannitol, fructose and 1,5-anhydroglucitol concentrations measured by gas chromatography/mass spectrometry in blood plasma of diabetic patients **251**, 91

Sakamoto, O., see Suzuki, Y. **251**, 41
Sattler, W., see Oettl, K. **251**, 131
Scheuring, E., see Beck, M. **251**, 163
Schlüter, K.-D., see Vorderwinkler, K.-P. **251**, 113
Seiffert, U.B., see Oremek, G.M. **251**, 201
Shibata, H., T. Yagi, Rate assay of *N*-acetyl- β -D-hexosaminidase with 4-nitrophenyl *N*-acetyl- β -D-glucosaminide as an artificial substrate **251**, 53
Spengler, U., see Fischer, S. **251**, 173
Steindel, S.J., B.A. Jones, P.J. Howanitz, Timeliness of automated routine laboratory tests: A College of American Pathologists Q-Probes study of 653 institutions **251**, 25
Suzuki, Y., Y. Aoki, O. Sakamoto, X. Li, S. Miyabayashi, Y. Kazuta, H. Kondo, K. Narisawa, Enzymatic diagnosis of holocarboxylase synthetase deficiency using apo-carboxyl carrier protein as a substrate **251**, 41

Voelter, H.-U., see Beck, M. **251**, 163

Yagi, T., see Shibata, H. **251**, 53
Yamada, T., T. Miida, Y. Itoh, T. Kawai, M.D. Benson, Characterization of serum amyloid A4 as a plasma apolipoprotein **251**, 53

Zwiebel, F.M., see Fischer, S. **251**, 173

Subject index

Volume 251 (1996)

ACAT; Lovastatin; Peroxisomes; Zellweger syndrome; Low density lipoproteins **251**, 131

N-Acetyl- β -D-hexosaminidase (EC 3.2.1.52); 4-Nitrophenyl *N*-acetyl- β -D-glucosaminide; Rate assay; Diethylaminoethyl- α -cyclodextrin **251**, 53

Acute myocardial infarction; Plasma annexin V; Monoclonal antibody; ELISA **251**, 65

Alcian blue complex; Glycosaminoglycans; Tamm-Horsfall glycoprotein; Urine **251**, 207

Apolipoprotein; Serum amyloid A; Isotype; High density lipoprotein; Very low density lipoprotein; Serum concentration **251**, 105

Autoantibody; Glutamic acid decarboxylase; Insulin-dependent diabetes mellitus; Enzyme-linked immunosorbent assay; **251**, 81

Bedside; Enzyme thermistor (ET); Glucose monitoring; Semi-continuous **251**, 187

Bile acids; Liver, cholestasis; Liver, cirrhosis; Gas chromatography **251**, 173

Blood plasma; Monosaccharides; Diabetes mellitus; Gas liquid chromatography; Peak deconvolution **251**, 91

Carboxyl carrier protein; Holocarboxylase synthetase; Multiple carboxylase deficiency; Fibroblasts **251**, 41

Colipase; Sodium deoxycholate; Titrimetry; Lyophilization; Reference material; Commutability **251**, 119

Commutability; Sodium deoxycholate; Colipase; Titrimetry; Lyophilization; Reference material **251**, 119

Creatine kinase; Lactate dehydrogenase; Troponin T; Troponin I; Langendorff heart; Rat; Myocardial hypoxia **251**, 113

Creatine kinase-isoenzyme MB; c-Troponin-T; Myocardial damage **251**, 201

Diabetes mellitus; Monosaccharides; Blood plasma; Gas liquid chromatography; Peak deconvolution **251**, 91

Diethylaminoethyl- α -cyclodextrin; *N*-Acetyl- β -D-hexosaminidase (EC 3.2.1.52); 4-Nitrophenyl *N*-acetyl- β -D-glucosaminide; Rate assay **251**, 53

ELISA; Plasma annexin V; Monoclonal antibody; Acute myocardial infarction **251**, 65

Enzyme activity; Reference material; Standardization **251**, 145

Enzyme-linked immunosorbent assay; Glutamic acid decarboxylase; Insulin-dependent diabetes mellitus; Autoantibody **251**, 81

Enzyme thermistor (ET); Glucose monitoring; Semi-continuous; Bedside **251**, 187

- Fibroblasts;** Holocarboxylase synthetase; Multiple carboxylase deficiency; Carboxyl carrier protein **251, 41**
- Galactosialidosis;** Neuraminidase; Sialidosis; Mucopolidosis; I-cell disease; In situ method **251, 163**
- Gas chromatography;** Bile acids; Liver, cholestasis; Liver, cirrhosis **251, 173**
- Gas liquid chromatography;** Monosaccharides; Blood plasma; Diabetes mellitus; Peak deconvolution **251, 91**
- Glucose monitoring;** Enzyme thermistor (ET); Semi-continuous; Bedside **251, 187**
- Glutamic acid decarboxylase;** Insulin-dependent diabetes mellitus; Enzyme-linked immunosorbent assay; Autoantibody **251, 81**
- Glycosaminoglycans;** Tamm-Horsfall glycoprotein; Alcian blue complex; Urine **251, 207**
- High density lipoprotein;** Serum amyloid A; Isotype; Apolipoprotein; Very low density lipoprotein; Serum concentration **251, 105**
- Holocarboxylase synthetase;** Multiple carboxylase deficiency; Fibroblasts; Carboxyl carrier protein **251, 41**
- I-cell disease;** Neuraminidase; Sialidosis; Mucopolidosis; Galactosialidosis; In situ method **251, 163**
- In situ method;** Neuraminidase; Sialidosis; Mucopolidosis; I-cell disease; Galactosialidosis **251, 163**
- Insulin-dependent diabetes mellitus;** Glutamic acid decarboxylase; Enzyme-linked immunosorbent assay; Autoantibody **251, 81**
- Isotype;** Serum amyloid A; Apolipoprotein; High density lipoprotein; Very low density lipoprotein; Serum concentration **251, 105**
- Laboratory Automation;** Routine test timeliness; Test turnaround times; Patient outcomes; Quality improvement; Quality assurance **251, 25**
- Lactate dehydrogenase;** Creatine kinase; Troponin T; Troponin I; Langendorff heart; Rat; Myocardial hypoxia **251, 113**
- Langendorff heart;** Creatine kinase; Lactate dehydrogenase; Troponin T; Troponin I; Rat; Myocardial hypoxia **251, 113**
- Liver, cholestasis;** Bile acids; Liver, cirrhosis; Gas chromatography **251, 173**
- Liver, cirrhosis;** Bile acids; Liver, cholestasis; Gas chromatography **251, 173**
- Lovastatin;** ACAT; Peroxisomes; Zellweger syndrome; Low density lipoproteins **251, 131**
- Low density lipoproteins;** ACAT; Lovastatin; Peroxisomes; Zellweger syndrome **251, 131**
- Lyophilization;** Sodium deoxycholate; Colipase; Titrimetry; Reference material; Commutability **251, 119**
- Monoclonal antibody;** Plasma annexin V; Acute myocardial infarction; ELISA **251, 65**
- Monosaccharides;** Blood plasma; Diabetes mellitus; Gas liquid chromatography; Peak deconvolution **251, 91**
- Mucopolidosis;** Neuraminidase; Sialidosis; I-cell disease; Galactosialidosis; In situ method **251, 163**
- Multiple carboxylase deficiency;** Holocarboxylase synthetase; Fibroblasts; Carboxyl carrier protein **251, 41**
- Myocardial damage;** Creatine kinase-isoenzyme MB; c-Troponin-T **251, 201**
- Myocardial hypoxia;** Creatine kinase; Lactate dehydrogenase; Troponin T; Troponin I; Langendorff heart; Rat **251, 113**
- Neuraminidase;** Sialidosis; Mucopolidosis; I-cell disease; Galactosialidosis; In situ method **251, 163**
- 4-Nitrophenyl N-acetyl- β -D-glucosaminide;** N-Acetyl- β -D-hexosaminidase (EC 3.2.1.52); Rate assay; Diethylaminoethyl- α -cyclodextrin **251, 53**

- Patient outcomes;** Routine test timeliness; Test turnaround times; Quality improvement; Laboratory automation; Quality assurance **251, 25**
- Peak deconvolution;** Monosaccharides; Blood plasma; Diabetes mellitus; Gas liquid chromatography **251, 91**
- Peroxisomes;** ACAT; Lovastatin; Zellweger syndrome; Low density lipoproteins **251, 131**
- Plasma annexin V;** Monoclonal antibody; Acute myocardial infarction; ELISA **251, 65**
- Quality improvement;** Routine test timeliness; Test turnaround times; Patient outcomes; Laboratory automation; Quality assurance **251, 25**
- Quality assurance;** Routine test timeliness; Test turnaround times; Patient outcomes; Quality improvement; Laboratory automation **251, 25**
- Rat;** Creatine kinase; Lactate dehydrogenase; Troponin T; Troponin I; Langendorff heart; Rat; Myocardial hypoxia **251, 113**
- Rate assay;** *N*-Acetyl- β -D-hexosaminidase (EC 3.2.1.52); 4-Nitrophenyl *N*-acetyl- β -D-glucosaminide; Diethylaminoethyl- α -cyclodextrin **251, 53**
- Reference material;** Sodium deoxycholate; Colipase; Titrimetry; Lyophilization; Commutability **251, 119**
- Reference material;** Enzyme activity; Standardization **251, 145**
- Routine test timeliness;** Test turnaround times; Patient outcomes; Quality improvement; Laboratory automation; Quality assurance **251, 25**
- Semi-continuous;** Enzyme thermistor (ET); Glucose monitoring; Bedside **251, 187**
- Serum amyloid A;** Isotype; Apolipoprotein; High density lipoprotein; Very low density lipoprotein; Serum concentration **251, 105**
- Serum concentration;** Serum amyloid A; Isotype; Apolipoprotein; High density lipoprotein; Very low density lipoprotein **251, 105**
- Sialidosis;** Neuraminidase; Mucopolidosis; I-cell disease; Galactosialidosis; In situ method **251, 163**
- Sodium deoxycholate;** Colipase; Titrimetry; Lyophilization; Reference material; Commutability **251, 119**
- Standardization;** Reference material; Enzyme activity **251, 145**
- Tamm-Horsfall glycoprotein;** Glycosaminoglycans; Alcian blue complex; Urine **251, 207**
- Test turnaround times;** Routine test timeliness; Patient outcomes; Quality improvement; Laboratory automation; Quality assurance **251, 25**
- Titrimetry;** Sodium deoxycholate; Colipase; Lyophilization; Reference material; Commutability **251, 119**
- Troponin I;** Creatine kinase; Lactate dehydrogenase; Troponin T; Langendorff heart; Rat; Myocardial hypoxia **251, 113**
- Troponin T;** Creatine kinase; Lactate dehydrogenase; Troponin I; Langendorff heart; Rat; Myocardial hypoxia **251, 113**
- c-Troponin-T;** Creatine kinase-isoenzyme MB; Myocardial damage **251, 201**
- Urine;** Glycosaminoglycans; Tamm-Horsfall glycoprotein; Alcian blue complex **251, 207**
- Very low density lipoprotein;** Serum amyloid A; Isotype; Apolipoprotein; High density lipoprotein; Serum concentration **251, 105**
- Zellweger syndrome;** ACAT; Lovastatin; Peroxisomes; Low density lipoproteins **251, 131**

The first part of the paper discusses the importance of the study of the history of the United States. It is argued that a knowledge of the past is essential for a full understanding of the present. The author then proceeds to a detailed examination of the early years of the Republic, from the time of the signing of the Declaration of Independence to the end of the War of 1812. This section covers the political, social, and economic developments of the period, and the role of the various states in the formation of the new nation.

The second part of the paper deals with the period from 1812 to 1860. This was a time of great change and growth for the United States. The author discusses the expansion of the territory, the development of the economy, and the increasing tensions between the North and the South. The role of the federal government in these developments is also examined. The author concludes this section by discussing the causes of the Civil War, which broke out in 1861.

The third part of the paper covers the period from 1861 to 1890. This was a time of reconstruction and rebuilding for the United States. The author discusses the efforts to rebuild the South after the war, the growth of the industrial revolution, and the increasing influence of the federal government. The author also discusses the role of the various states in these developments. The section concludes with a discussion of the Gilded Age, a period of great wealth and corruption.

The fourth part of the paper deals with the period from 1890 to 1914. This was a time of great change and growth for the United States. The author discusses the expansion of the territory, the development of the economy, and the increasing tensions between the North and the South. The role of the federal government in these developments is also examined. The author concludes this section by discussing the causes of the Civil War, which broke out in 1861.

The fifth part of the paper covers the period from 1914 to 1945. This was a time of great change and growth for the United States. The author discusses the expansion of the territory, the development of the economy, and the increasing tensions between the North and the South. The role of the federal government in these developments is also examined. The author concludes this section by discussing the causes of the Civil War, which broke out in 1861.

The sixth part of the paper deals with the period from 1945 to 1970. This was a time of great change and growth for the United States. The author discusses the expansion of the territory, the development of the economy, and the increasing tensions between the North and the South. The role of the federal government in these developments is also examined. The author concludes this section by discussing the causes of the Civil War, which broke out in 1861.

The seventh part of the paper covers the period from 1970 to 1990. This was a time of great change and growth for the United States. The author discusses the expansion of the territory, the development of the economy, and the increasing tensions between the North and the South. The role of the federal government in these developments is also examined. The author concludes this section by discussing the causes of the Civil War, which broke out in 1861.

The eighth part of the paper deals with the period from 1990 to the present. This was a time of great change and growth for the United States. The author discusses the expansion of the territory, the development of the economy, and the increasing tensions between the North and the South. The role of the federal government in these developments is also examined. The author concludes this section by discussing the causes of the Civil War, which broke out in 1861.